Status:
COMPLETED
Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
Lead Sponsor:
Bial - Portela C S.A.
Conditions:
Parkinson Disease
Eligibility:
MALE
40-55 years
Phase:
PHASE1
Brief Summary
To determine the absorption, metabolism and excretion of BIA 9-1067.
Detailed Description
Monocentre, open, non-placebo-controlled, single-group, single-dose study
Eligibility Criteria
Inclusion
- Healthy Caucasian male subjects, 40-55 years of age.
- Sitting blood pressure and pulse rate within a clinically acceptable range for the purposes of the study, i.e.: BP: 100 - 160 mmHg systolic, 50 - 95 mmHg diastolic and pulse rate: 50 - 100 bpm. Blood pressure and pulse were to be measured after 3 minutes resting in a sitting position.
- Subject body mass index was to be between 18 and 28 kg/m2
- Normal 12-lead ECG
- Ability to communicate well with the investigator and comply with the requirements of the entire study.
- The subject had given his written informed consent to participate in the study.
Exclusion
- History of serious adverse reactions or hypersensitivity to any drug.
- Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
- History of alcohol or drug abuse in the last 5 years.
- Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
- Need of any prescription medication within 14 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug.
- Participation in other clinical trials during the previous month in which an investigational drug or a commercially available drug was tested.
- Loss of 500 mL blood or more during the 3 month period before the study, e.g., as a donor.
- Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e., impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract.
- Symptoms of a significant somatic or mental illness in the 4 week period preceding drug administration.
- History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.
- Positive results from the HIV serology.
- Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation, however, liver parameters (SGPT, SGOT) values must be within the normal range.
- Positive results of the drug screening.
- Known hypersensitivity to BIA 9-1067.
- Heavy smokers, i.e., more than 10 cigarettes per day
- Exposure to artificial ionizing radiation in the last 12 months (e.g., x-ray investigation)
- Subject who had more than 4 flights (with more than 2 hours flight time) within the last year prior to the administration of the drug.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01515891
Start Date
May 1 2009
End Date
September 1 2010
Last Update
January 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Basel Research Unit AG (formerly Swiss Pharma Contract Ltd)
Allschwil, Base, Switzerland, CH-4123